CRX100 Elicits Activity, Is Well Tolerated in Recurrent, Platinum-Resistant Ovarian Cancer

19 Mar CRX100 Elicits Activity, Is Well Tolerated in Recurrent, Platinum-Resistant Ovarian Cancer Posted at 18:15h in News by Diana Share March 19, 2024 Russ Conroy, OncLive Combination treatment with the novel adoptive Natural Killer-Like T (NK-T) cell therapy CRX100 and a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in a small cohort of patients with recurrent, platinum-resistant ovarian cancer, according to data from a phase 1 trial (NCT04282044) presented at the 2024 SGO Annual Meeting on Women’s Cancer.1 Investigators reported stable disease in 1 patient who received an initial dose of 1E8 plaque-forming units (PFUs) of vaccinia plus 2-5E9 NK-T cells. Additionally, the patient had reduced tumor burden following a second dose of CRX100. This patient received subsequent treatment with an experimental antibody-drug conjugate plus pembrolizumab (Keytruda), which reduced CA125 serum marker levels to 296 U/mL. Of 7 patients, 5 were alive at 1 to 36 months following treatment with CRX100. Two patients died due to progressive disease. Findings highlighted that interferon-γ levels increased with study treatment, suggesting that CRX100 may produce an inflammatory tumor microenvironment that can delay antitumor responses and augment subsequent immunotherapy activity. “This is the first-in-human trial using adoptive NK-T cell transfer combined with an oncolytic vaccinia virus,” Oliver Dorigo, MD, PhD, a Mary Lake Professor in Obstetrics & Gynecology – Gynecologic Oncology at Stanford Women’s Cancer Center, Stanford University and coauthors, wrote in the poster. Read Full OncLive Article SGO Poster 2024 (PDF)

The release as fetched from its publisher. bioeclipse.com ↗